|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||600.00 - 600.00|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
I am going to take a deep dive into Galena Biopharma Inc’s (NASDAQ:GALE) most recent ownership structure, not a frequent subject of discussion among individual investors. Ownership structure has beenRead More...
LONDON, UK / ACCESSWIRE / January 03, 2018 / Active-Investors.com has just released a free research report on Galena Biopharma, Inc. (NASDAQ: GALE ).If you want access to this report all you need to do ...
If you are a shareholder in Galena Biopharma Inc’s (NASDAQ:GALE), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...
In addition to giving a nod to the SELLAS alliance, the GALE board has likewise set into motion a reverse stock split ratio. One proposal, regarding approval of an amendment to Galena’s Certificate of Incorporation to allow the Galena board of directors to approve amendments to Galena’s bylaws, was not approved.